10 Best Performing Mid Cap Stocks to Buy According to Analysts

7. Guardant Health Inc. (NASDAQ:GH)

Year-to-Date Performance as of February 24: 39.74%

Upside Potential as of February 24: 31.15%

Number of Hedge Fund Holders: 40

Guardant Health Inc. (NASDAQ:GH) is a precision oncology company that specializes in liquid biopsies and advanced analytics. It offers tests and platforms to detect, monitor, and inform treatment decisions for cancer patients. It uses AI and extensive data to drive advancements in personalized cancer care.

The company’s therapy selection, driven by Guardant360, is a key revenue generator. Guardant360 is a liquid biopsy test that analyzes circulating tumor DNA in the bloodstream to identify genomic alterations in advanced solid tumors. This aids in personalized cancer treatment decisions. In Q4 2024, clinical revenue grew 34% year-over-year. Guardant360 volumes saw double-digit growth in 2024 and contributed to a 24% increase in Q4 clinical test volumes. Guardant360’s average selling price reached $3,000 in Q4 2024, ahead of the 2028 target, due to Medicare rate increases and improved commercial collections. The upgraded Guardant360 Liquid enhances gene coverage and sensitivity on the Smart Liquid Biopsy platform, which drives increased test frequency.

In mid-January, Guardant Health Inc. (NASDAQ:GH) entered a collaboration with ConcertAI, where it’s using AI to integrate patient electronic medical record (EMR) data with tumor profiling to create a real-world data solution for biopharma partners. This is to enhance disease biology interpretation, identify tumor evolution mechanisms, and improve cancer treatment development through advanced data and AI analytics.